The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients

Basit Öğe Kaydı
dc.authoridSerdar Çevik / 0000-0002-2733-4233
dc.authorscopusidSerdar Çevik / 56516611400
dc.authorwosidSerdar Çevik / G-7161-2018
dc.contributor.authorÇevik, Serdar
dc.contributor.authorKitis, S.
dc.contributor.authorEvran, S.
dc.contributor.authorAkkaya, E.
dc.contributor.authorTosuner, Z.
dc.contributor.authorHanimoglu, H.
dc.date.accessioned2020-08-30T20:07:38Z
dc.date.available2020-08-30T20:07:38Z
dc.date.issued2018
dc.departmentİstinye Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Anestezi Bölümüen_US
dc.description.abstractBackground: Glioblastoma multiforme (GBM) is the most common primary brain tumor characterized with poor prognosis and short survival. In addition to the standard treatment protocols, targeted molecular treatment options are under trial. In the recent trials, erythropoietin and erythropoietin receptor were found to be linked with the progression of GBM cells. Aim: In this study, we compared the expression of EPOR with survival in GBM patients with mortality. Materials and Methods: Twenty-six patients operated for GBM in 2012u2014 were enrolled in this study. Tumor tissues were stained with EPOR, epidermal growth factor receptor, vascular endothelial growth factor, and assigned as (1+), (2+), and (3+) according to their immunohistochemical staining levels. The average postoperative follow-up time was 9.3 months. KaplanuMeier's survival test and Spearman's correlation test were used in statistical analysis. Results: EPOR 1(+) stained group showed a median survival of 8 months (95% confidence interval [CI]: 0.954u15.046). EPOR 2(+) stained group showed a median survival of 6 months (95% CI: 2.901u9.090) EPOR 3(+) stained group showed a median survival of 2 months (95% CI: 0.400u3.600). (KaplanuMeier P = 0.002). Conclusion: These results portrayed that EPOR staining levels were inversely proportional with average survival time. In the future, specific inhibitors of this molecule could be used to form a novel treatment option for GBM.en_US
dc.identifier.citationCevik, S., Kitis, S., Evran, S., Akkaya, E., Tosuner, Z., & Hanimoglu, H. (2018). The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients. Nigerian journal of clinical practice, 21(4).en_US
dc.identifier.doi10.4103/njcp.njcp_126_17en_US
dc.identifier.endpage506en_US
dc.identifier.issn1119-3077en_US
dc.identifier.issue4en_US
dc.identifier.pmid29607865en_US
dc.identifier.scopus2-s2.0-85045146319en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage502en_US
dc.identifier.urihttps://doi.org/10.4103/njcp.njcp_126_17
dc.identifier.urihttps://hdl.handle.net/20.500.12713/803
dc.identifier.volume21en_US
dc.identifier.wosWOS:000429375500016en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÇevik, Serdaren_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofNigerian Journal of Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEpidermal Growth Factor Receptoren_US
dc.subjectErythropoietin Receptoren_US
dc.subjectGlioblastoma Multiformeen_US
dc.subjectPrognosisen_US
dc.subjectSurvivalen_US
dc.subjectVascular Endothelial Growth Factoren_US
dc.titleThe relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
305.pdf
Boyut:
1.64 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Anestezi Programı Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu